Clinical Trials
S-1 With Cisplatin Shows Comparable Safety and 5-FU AUC in Severe Hepatic Dysfunction
Gwee et alFrontiers in oncology

Patients with advanced solid tumors and severe hepatic dysfunction have limited systemic therapy options due to impaired drug clearance and the potential for heightened toxicity. Consequently, this patient group is frequently excluded from clinical trials. A prospective study evaluated the feasibility, safety, pharmacokinetics, and preliminary efficacy of oral S-1 combined with intravenous cisplatin in this underrepresented population.
Between September 2016 and November 2023, 61 patients were enrolled and categorized into four cohorts according to the National Cancer Institute Organ Dysfunction Working Group (NCI-ODWG) criteria: normal hepatic function (Cohort 1), mild dysfunction (Cohort 2), moderate dysfunction (Cohort 3), and severe dysfunction (Cohort 4). The primary endpoints evaluated safety and 5-fluorouracil (5-FU) pharmacokinetics, while secondary endpoints assessed objective response rate (ORR) and 3-month clinical benefit rate (3M-CBR).
Pharmacokinetic analysis on Cycle 1 Day 15 showed that patients with severe hepatic dysfunction had a lower 5-FU Cmax and longer Tmax compared to those in Cohort 1 (p<0.05); however, overall 5-FU AUC remained comparable across all cohorts. Safety profiles across Cohort 4 were similar to Cohorts 1 through 3, and no grade 5 treatment-related adverse events were observed. Within Cohort 4, 22.2% of patients achieved a partial response, 40.7% experienced clinical benefit, and 22.2% maintained progression-free survival for 6 months or longer. The authors concluded that cisplatin plus S-1 may be feasible in selected patients with severe hepatic dysfunction, noting that larger studies are needed to further define its clinical activity and safety profile.
Key Takeaways
- In patients with severe hepatic dysfunction (Cohort 4), the regimen achieved a 22.2% partial response rate, a 40.7% clinical benefit rate, and progression-free survival of at least 6 months in 22.2%.
- Safety outcomes in Cohort 4 were similar to those with normal, mild, or moderate hepatic dysfunction, with no grade 5 treatment-related adverse events reported.
- On Cycle 1 Day 15, severe hepatic dysfunction was associated with a lower 5-FU Cmax and longer Tmax compared to normal hepatic function (p<0.05), while 5-FU AUC was comparable across all cohorts.
Read the original sourceFrontiers in oncology
